On Tuesday, Aditxt Inc. (ADTX) announced that its wholly owned subsidiary, Ignite Proteomics, signed a definitive business combination agreement that values the precision oncology company at approximately $150 million. The deal is designed to separate Ignite from Aditxt and turn it into an independent public company through a newly formed holding company, expected to be named Ignite Proteomics Inc. Aditxt itself is expected to remain a separate Nasdaq-listed company, subject to continued compliance with listing requirements.
After the deal closes, Ignite and the acquisition corporation will become wholly owned subsidiaries of the new holding company. Ignite's common stock and public warrants are expected to trade on the New York Stock Exchange, pending regulatory approvals and customary closing conditions.
Ignite develops a functional proteomics platform that directly measures protein and phosphoprotein activity in tumor tissue to support precision oncology treatment decisions. Right now, the company focuses on breast cancer, but it plans to expand into additional tumor types.
Aditxt said the transaction is intended to unlock the value of its 100%-owned subsidiary while giving Ignite more visibility and access to growth capital. The proceeds are expected to fund commercialization efforts, clinical evidence generation, and general corporate purposes. The deal still needs shareholder, regulatory, and listing approvals.














